Becton Dickinson management check
BDX · Health Care · Health Care Equipment · CEO Thomas E. Polen
Filings as of
Closest peers in Health Care Equipment
- 153ISRGIntuitive Surgical72
- 158ABTAbbott Laboratories72
- 162SYKStryker Corporation71
- 185IDXXIdexx Laboratories69
- 199BSXBoston Scientific68
- 250RVTYRevvity64
- 284RMDResMed63
- 286GEHCGE HealthCare62
- 322STESteris60
- 353BDXBecton Dickinson58
The seven checks
- FlagTrailed its chosen peers
Have owners done well?
What $100 became since fiscal 2021
1124thDetail
$100 invested at the start of fiscal 2021 grew to $89, against $130 for the peer group the company picked itself.
- GoodPay rose and fell with returns
Does pay follow performance?
Pay actually paid $100 value, each on its own scale
8965thDetail
Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.78 with shareholder return. 1 means pay moved in step; below 0, the opposite way.
- Watch1.0% of net income
What does the CEO cost owners?
$17.1m pay · $1.7bn net income, FY2025
4950thDetail
$17.1m of reported pay in fiscal 2025, against $1.7bn of net income.
- WatchCEO stake ≈ 1.6 years of pay
Do they own the stock?
130,402 shares ≈ $27.4m
6 mo: ▲ $0 bought · ▼ $2.7m sold
4549thDetail
The CEO holds 130,402 shares, directly or through trusts (unvested awards not counted): about 1.6 years of pay. Light activity: no buys, $2.7m sold in six months. 11 of 12 sales ran on pre-arranged 10b5-1 plans.
- WatchShare count growing
Are owners being diluted?
Diluted shares +0.0% a year; flagged above +2%
Stock pay 1.2% of revenue
5034thDetail
Diluted shares changed +0.0% a year over the last three fiscal years. Stock-based pay was 1.2% of revenue in the latest year.
- Watch13 leadership filings in 3 years
Is leadership stable?
13 filings under 8-K 5.02 in 3 years
CEO: Thomas E. Polen
6038thDetail
CEO in the pay table: Thomas E. Polen. 13 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.
- GoodNo red flags on file
Are the books clean?
Since 2021
- 0Restated
- 0Auditor changes
- 0Late filings
- 010-K amended
100100thDetail
No restatements, auditor changes or late filings since 2021.
Reading the scores
Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.
Hover a chart for its figures. Detail has the full reading.
Pay versus performance
From the proxy statement filed December 18, 2025.
Pay tied most to Revenue
Other key measuresRevenue*Adjusted EPS*Free cash flow*Operating margin*ROIC*
Show the figures
| Fiscal year | CEO | CEO pay | Actually paid | Other executives (avg) | $100 became | Peers | Net income |
|---|---|---|---|---|---|---|---|
| 2025 | Thomas E. Polen | $17.1m | $3.5m | $4.3m | $89 | $130 | $1.7bn |
| 2024 | — | $17.3m | $9.5m | $4.0m | $113 | $127 | $1.7bn |
| 2023 | — | $17.3m | $29.8m | $4.5m | $119 | $102 | $1.5bn |
| 2022 | — | $16.7m | $15.0m | $4.2m | $101 | $90 | $1.8bn |
| 2021 | — | $14.2m | $16.7m | $3.7m | $107 | $127 | $2.1bn |
Insiders and the CEO's stakeQuiet
- Chairman, CEO and President
- Thomas E Jr Polen
- Shares held
- 130,402
- At that filing's price
- ≈ $27.4m
- Latest Form 4
- Nov 5, 2026
Light activity: no buys, $2.7m sold in six months. 11 of 12 sales ran on pre-arranged 10b5-1 plans.
Open-market trades by officers and directors since May 21, 2026.
- SoldThomas E Jr PolenChairman, CEO and President · 10b5-1 plan$1.8mNov 5, 2026
- SoldRoland GoetteEVP and President, EMEA$441kAug 11, 2026
- SoldMichael David GarrisonEVP & Pres Med.Essntl&BioPharm · 10b5-1 plan$327kJun 24, 2026
- SoldMichael FeldEVP, Chief Revenue Officer · 10b5-1 plan$94kOct 26, 2026
Leadership and governance on file
All 20 filings
- Jul 22, 2026Leadership change8-K 5.02
- May 7, 2026Leadership change8-K/A 5.02
- Apr 9, 2026Leadership change8-K 5.02
- Feb 9, 2026Leadership change8-K 5.02
- Jan 30, 2026Leadership change8-K 5.02
- Dec 1, 2025Leadership change8-K/A 5.02
- Nov 17, 2025Leadership change8-K 5.02
- Oct 15, 2025Leadership change8-K 5.02
- Mar 27, 2025Leadership change8-K 5.02
- Jan 10, 2025Leadership change8-K 5.02
- Aug 30, 2024Leadership change8-K 5.02
- Feb 27, 2024Leadership change8-K 5.02
- Nov 27, 2023Leadership change8-K 5.02
- Jul 24, 2023Leadership change8-K 5.02
- Jan 30, 2023Leadership change8-K 5.02
- Jan 6, 2023Leadership change8-K 5.02
- Aug 25, 2022Leadership change8-K 5.02
- Apr 6, 2022Leadership change8-K 5.02
- Mar 31, 2022Leadership change8-K 5.02
- Mar 1, 2022Leadership change8-K 5.02
Latest shareholder vote results: Jan 30, 2026, including the say-on-pay vote.
Where the money went
2021–2025: $9.3bn returned to owners in buybacks and dividends, 106% of net income, and $1.2bn of pay in stock.
Show the figures
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $19.1bn | $18.9bn | $19.4bn | $20.2bn | $21.8bn |
| Net income | $2.1bn | $1.8bn | $1.5bn | $1.7bn | $1.7bn |
| Stock-based pay | $229.0m | $233.0m | $259.0m | $247.0m | $258.0m |
| Buybacks | $1.8bn | $500.0m | $0 | $500.0m | $1.0bn |
| Dividends | $1.0bn | $1.1bn | $1.1bn | $1.1bn | $1.2bn |
| Diluted shares | 292m | 287m | 288m | 291m | 289m |
Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.